Mission Bio Inc.
400 E Jamie Ct.
South San Francisco
Tel: (415) 854-0058
About Mission Bio Inc.
Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies. Mission Bio's multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.
The company's Tapestri platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies worldwide to develop treatments and eventually cures for cancer.
Visit missionbio.com to learn more.
Characterize your cell and gene therapies better with Tapestri CGT Solutions. Develop safe and efficacious therapies with single-cell analysis. Measure genomic alterations from virus and CRISPR, along with immunophenotype.
All with single-cell resolution.
No cell culture required.
Shorten your workflow from weeks to days.
Partner with our skilled scientific team to develop your assay.
Gain confidence in your therapies so they can reach patients faster.
48 articles about Mission Bio Inc.
Mission Bio names Josep Carreras Leukaemia Research Institute as First Center of Excellence for Tapestri Platform in Europe
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a new Center of Excellence, located at the Josep Carreras Leukaemia Research Institute and led by Manel Esteller, MD, PhD.
Mission Bio, Inc. today announced the appointment of Todd Druley , MD, PhD.
Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, launched the Tapestri Solution for Solid Tumor Research.
Mission Bio Inc. , the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced it has appointed Stuart Essig, PhD, as Chair of its Board of Directors.
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced its first Center of Excellence, located at Memorial Sloan Kettering Cancer Center (MSK) and run by Jorge Reis-Filho, MD, PhD.
Mission Bio Transfers First Tapestri GMP-Ready CGT Assay to Avance Biosciences for Cell-Based Therapies
Mission Bio , the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced today the first tech transfer of a clinical trial-ready cell and gene therapy (CGT) assay from its Tapestri Platform to Avance Biosciences, Inc.
Mission Bio and SequMed Sign Collaboration Agreement Announcing Partnership to Provide Tapestri Services and Co-Develop Clinical Applications in China
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, has signed an agreement with SequMed, a pioneer in single-cell omics technology innovation and applications in China.
Mission Bio's Tapestri Platform Helps Elucidate Resistance Mechanisms to Lung Cancer Drugs in Nature Publication
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced a publication in Nature led by researchers from Memorial Sloan Kettering Cancer Center that could broaden the potential benefits for KRAS G12C inhibitors like sotorasib in patients with lung cancer and other solid tumors.
Celares and Mission Bio are part of the rapidly evolving push to create and characterize the superhuman powers cells can be endowed with.
Mission Bio Updates Tapestri Platform to Enable a Broader Range of Single Cell Studies in Heme-Oncology Research
Mission Bio today announced two key improvements to the core capabilities of its Tapestri Platform intended to expand its accessibility and utility in the area of hematologic oncology (heme-onc) research.
Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainland China .
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced a new peer-reviewed study published using the Tapestri Platform's single-cell multi-omics solution to accurately distinguish leukemic cells from clonal hematopoiesis of indeterminate potential in relapsed AML patients.
The novel study showcases a cancer-like paradigm in cerebral cavernous malformations (CCM), a poorly understood, yet aggressive disease
Mission Bio just launched its Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on its existing products.
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of its Pharma Assay Development services to accelerate biomarker discovery and cell and gene therapy development pipelines for biopharma customers.
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the appointment of Yan Zhang to the role of CEO.
She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio's Tapestri Platform
Validates multi-omics techniques for measuring therapeutic responses to AML, holding promise for future blood cancer treatments
Resistance Mechanisms to FLT3 Inhibitor for AML Characterized Using Mission Bio's Tapestri Platform in Newly Published Study
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, has announced that its Tapestri Platform was used in a new study published Friday in Blood Advances to characterize the complex clonal heterogeneity that leads to treatment resistance of the FLT3 inhibitor quizartinib in patients with acute myeloid leukemia.
Mission Bio’s Tapestri Platform is the first-ever single-cell multi-omics platform capable of identifying cancer cell mutation profiles.